{"pmid":32441787,"title":"A Rare Case of Immune Thrombocytopenic Purpura Secondary to COVID-19.","text":["A Rare Case of Immune Thrombocytopenic Purpura Secondary to COVID-19.","Coronavirus Disease 2019 (COVID-19) is a newly emerging infectious disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After its first occurrence in Wuhan of China from December 2019, COVID-19 rapidly spread around the world. Studies have shown that coagulation dysfunction is one of the important reason causing death of COVID-19 patients and appeared in many patients. However, cases of COVID-19 with immune thrombocytopenic purpura were very rare. Here, a patient with immune thrombocytopenic purpura in Huoshenshan Hospital (Wuhan, China) was reported, whose laboratory data, clinical treatment and hospital outcome was described in this study. Fortunately, immune thrombocytopenic purpura with COVID-19 of the patient was diagnosed and treated in time and cured eventually. This case illustrates the need to be vigilant for complications associated with COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Yang, Yang","Zhao, Jun","Wu, Jian","Teng, Yi","Xia, Xinyi","32441787"],"abstract":["Coronavirus Disease 2019 (COVID-19) is a newly emerging infectious disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After its first occurrence in Wuhan of China from December 2019, COVID-19 rapidly spread around the world. Studies have shown that coagulation dysfunction is one of the important reason causing death of COVID-19 patients and appeared in many patients. However, cases of COVID-19 with immune thrombocytopenic purpura were very rare. Here, a patient with immune thrombocytopenic purpura in Huoshenshan Hospital (Wuhan, China) was reported, whose laboratory data, clinical treatment and hospital outcome was described in this study. Fortunately, immune thrombocytopenic purpura with COVID-19 of the patient was diagnosed and treated in time and cured eventually. This case illustrates the need to be vigilant for complications associated with COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Yang, Yang","Zhao, Jun","Wu, Jian","Teng, Yi","Xia, Xinyi"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441787","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26051","keywords":["coronavirus < virus classification","disease control","immune responses"],"locations":["Wuhan","China","Huoshenshan Hospital","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1667523504786898945,"score":9.490897,"similar":[{"pmid":32314799,"title":"Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.","text":["Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.","Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Morrison, Austin R","Johnson, Joseph M","Ramesh, Mayur","Bradley, Patrick","Jennings, Jeffery","Smith, Zachary R","32314799"],"abstract":["Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Morrison, Austin R","Johnson, Joseph M","Ramesh, Mayur","Bradley, Patrick","Jennings, Jeffery","Smith, Zachary R"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314799","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25907","keywords":["coronavirus","disease control","immune responses","immunodulators","interleukin","virus classification"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138493493968898,"score":156.57777},{"pmid":32491234,"title":"Retiform purpura as a dermatological sign of covid-19 coagulopathy.","text":["Retiform purpura as a dermatological sign of covid-19 coagulopathy.","Since December 2019, coronavirus disease 2019 (COVID-19) has spread worldwide to become a pandemic. Multiple skin manifestations related to the infection have been described progressively. Recalcati(1) asserted that 20.4% of infected patients developed cutaneous manifestations and Galvan-Casas et al(2) have recently proposed 5 clinical patterns (pseudo-chilblain, vesicular, urticarial, maculopapular and livedo/necrosis). We report a case of COVID-19 with retiform purpura and its histopathological correlation.","J Eur Acad Dermatol Venereol","Bosch-Amate, X","Giavedoni, P","Podlipnik, S","Andreu-Febrer, C","Sanz-Beltran, J","Garcia-Herrera, A","Alos, L","Mascaro, J M Jr","32491234"],"abstract":["Since December 2019, coronavirus disease 2019 (COVID-19) has spread worldwide to become a pandemic. Multiple skin manifestations related to the infection have been described progressively. Recalcati(1) asserted that 20.4% of infected patients developed cutaneous manifestations and Galvan-Casas et al(2) have recently proposed 5 clinical patterns (pseudo-chilblain, vesicular, urticarial, maculopapular and livedo/necrosis). We report a case of COVID-19 with retiform purpura and its histopathological correlation."],"journal":"J Eur Acad Dermatol Venereol","authors":["Bosch-Amate, X","Giavedoni, P","Podlipnik, S","Andreu-Febrer, C","Sanz-Beltran, J","Garcia-Herrera, A","Alos, L","Mascaro, J M Jr"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32491234","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/jdv.16689","keywords":["covid-19","cutaneous manifestation","retiform purpura","skin"],"topics":["Diagnosis"],"weight":1,"_version_":1668892169350414337,"score":149.10158},{"pmid":32383234,"title":"Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): a brief review.","text":["Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): a brief review.","COVID-19, first appeared in December 2019 in Wuhan, China, has been spreading quickly throughout the world. We reviewed the evidence on cutaneous manifestations of COVID-19 based on PubMed database. The searching strategy was (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. After independent review by two authors, 14 studies with 228 confirmed cases were included in the analysis. A total of 60 patients developed skin rashes, and the age ranged from 8 to 84. Exanthematous eruptions potentially related to COVID-19 infection were highly variable and heterogeneous. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox-like or varicelliform). Petechiae rash, livedo reticularis, and reactivation of oral HSV-1 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis-like) skin lesions caused concern among dermatologists. Exanthems were widely distributed and were primarily located on the trunk. Associated symptoms, latency time, treatment, and prognosis were also carefully summarized. This study reviewed the recently published COVID-19 studies with skin manifestations, which may pave the way for further research. This article is protected by copyright. All rights reserved.","Dermatol Ther","Tang, Keyun","Wang, Yuanzhuo","Zhang, Hanlin","Zheng, Qingyue","Fang, Rouyu","Sun, Qiuning","32383234"],"abstract":["COVID-19, first appeared in December 2019 in Wuhan, China, has been spreading quickly throughout the world. We reviewed the evidence on cutaneous manifestations of COVID-19 based on PubMed database. The searching strategy was (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. After independent review by two authors, 14 studies with 228 confirmed cases were included in the analysis. A total of 60 patients developed skin rashes, and the age ranged from 8 to 84. Exanthematous eruptions potentially related to COVID-19 infection were highly variable and heterogeneous. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox-like or varicelliform). Petechiae rash, livedo reticularis, and reactivation of oral HSV-1 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis-like) skin lesions caused concern among dermatologists. Exanthems were widely distributed and were primarily located on the trunk. Associated symptoms, latency time, treatment, and prognosis were also carefully summarized. This study reviewed the recently published COVID-19 studies with skin manifestations, which may pave the way for further research. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Tang, Keyun","Wang, Yuanzhuo","Zhang, Hanlin","Zheng, Qingyue","Fang, Rouyu","Sun, Qiuning"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383234","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/dth.13528","keywords":["covid-19","coronavirus","cutaneous manifestations","review","skin"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666267276793348098,"score":145.45226},{"pmid":32342677,"title":"Severe Thrombocytopenia in a Patient with COVID-19.","text":["Severe Thrombocytopenia in a Patient with COVID-19.","Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm(3) and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.","Infect Chemother","Nham, Eliel","Ko, Jae Hoon","Jeong, Byeong Ho","Huh, Kyungmin","Cho, Sun Young","Kang, Cheol In","Chung, Doo Ryeon","Peck, Kyong Ran","32342677"],"abstract":["Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm(3) and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered."],"journal":"Infect Chemother","authors":["Nham, Eliel","Ko, Jae Hoon","Jeong, Byeong Ho","Huh, Kyungmin","Cho, Sun Young","Kang, Cheol In","Chung, Doo Ryeon","Peck, Kyong Ran"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32342677","source":"PubMed","week":"202018|Apr 27 - May 03","keywords":["covid-19","ceftriaxone, levofloxacin","lopinavir/ritonavir","thrombocytopenia"],"locations":["Thrombocytopenia"],"e_drugs":["Ceftriaxone","lopinavir-ritonavir drug combination","Levofloxacin"],"topics":["Case Report"],"weight":1,"_version_":1666138495809224708,"score":133.22128},{"pmid":32472706,"title":"The Long-Standing History of Corynebacterium Parvum, Immunity and Viruses.","text":["The Long-Standing History of Corynebacterium Parvum, Immunity and Viruses.","We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium Parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activity, but the interest to successfully prevent and treat bacterial, fungal and viral infections and lethality, uprising the innate immunity barriers produced many experimental models and very few clinical studies. The dramatic defenceless situation due to impending CoViD-19 pandemic claims to exhume and highlight this aspecific strategy in preventive and therapeutic settings; as a matter of fact no new or mutated virus can potentially escape to this strong innate immune surveillance strengthened by adequate C.parvum protocols. This article is protected by copyright. All rights reserved.","J Med Virol","Palmieri, Beniamino","Vadala, Maria","Roncati, Luca","Garelli, Andrea","Scandone, Francesco","Bondi, Moreno","Cermelli, Claudio","32472706"],"abstract":["We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium Parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activity, but the interest to successfully prevent and treat bacterial, fungal and viral infections and lethality, uprising the innate immunity barriers produced many experimental models and very few clinical studies. The dramatic defenceless situation due to impending CoViD-19 pandemic claims to exhume and highlight this aspecific strategy in preventive and therapeutic settings; as a matter of fact no new or mutated virus can potentially escape to this strong innate immune surveillance strengthened by adequate C.parvum protocols. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Palmieri, Beniamino","Vadala, Maria","Roncati, Luca","Garelli, Andrea","Scandone, Francesco","Bondi, Moreno","Cermelli, Claudio"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472706","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26100","keywords":["c.parvum","coronavirus < virus classification","epidemiology","immune responses","immunomodulation < immune responses","innate immunity < immune responses"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668255193479774208,"score":132.56093}]}